98 % of the human population is chronically infected by EBV. We propose an innovative platform for engineering
immunogenic bi-modular fusion proteins comprising a binding moiety and an EBV antigen to redirect an EBV preexisting
immune response towards a select cellular target. The aim is to develop efficient therapies triggering immune
mechanisms such as Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-mediated Cytotoxicity
(ADCC) and Antibody- Dependent Phagocytosis (ADP) to combat pathogens or treat pathologies such as cancer.
Competitive advantages :
Keywords : Epstein-Barr Virus - Therapeutic molecular engineering - Antibody
fragments - Nanobodies - Immune effectors - Cellular cytotoxicity /